Advances in the Pharmacotherapy of Periodontal and Oral Mucosal Diseases
Authors:
R. Slezák 1; Lenka Ryšková 2
; V. Paulusová 1; Z. Šustová 1; I. Berglová 1; V. Buchta 2
Authors place of work:
Stomatologická klinika LF UK a FN, Hradec Králové
1; Ústav klinické mikrobiologie LF UK a FN, Hradec Králové
2
Published in the journal:
Česká stomatologie / Praktické zubní lékařství, ročník 112, 2012, 1, s. 15-22
Category:
Review Article
Summary
Introduction:
There are many of drugs useful for topical or systemic treatment of diseases of periodontal tissue and oral mucous membrane. Their correct administration and efficacy depend strictly on adeqnate of information regarding their properties.
Aim:
The review deals with some drugs newly available in Czech Republic and related therapeutic procedures used in the treatment of periodontal and mucosal diseases.
Therapeutic agents:
For topical chemical inhibition of the dental plaque are dedicated octenidine, kationic antiseptic pyridine derivate, and combination of classic bis-biguanide derivate chlorhexidine with aromatic agent eugenol. As adjuvant chemotherapeutics in the treatment of periodontitis serve systems for targeted antimicrobial photodynamic therapy based on the use of photosensitizers as producers of the singlet oxygen, namely toluidine blue O and methylen blue. The source of monochromatic light for their pohotoactivation is laser device. Saturated alcohol docosanol with antiviral acitivity serves in topical therapy of labial herpes. Vanillinamide alkaloid capsaicine is selective agonist of vanilloid receptore TRPV 1 of sensitive nerves. Patch product Qutenza has been recently used for higly effective topical treatment of neuropatic pain. It could be potentially very useful agent in the treatment of some forms of atypical facial pain. Irradiation of salivary glands results in association with its dosis in the damage of various grade of the glandular parenchyma associated with postirradiative hyposialia. Cytoprotective prodrug amifostine releases active thiol after its dephosphorylation. It is recommended for the protection of the glandular parenchyma against adverse effects of antitumorous drugs and therapeutic irradiation in the region of the head and neck.
Conclusion:
Spectrum of therapeutic agents useful in the treatment of periodontal and mucosal diseases raises permanently. Efficacy of their application is connected with sufficient information of professionals and correct and early diagnosis of the disease, as well.
Key words:
periodontal tissue – oral mucous membrane – antimicrobial photodynamic therapy – toluidine blue O – methylen blue – octenidine – chlorhexidine – eugenol – docosanol – capsaicine – amifostine
Zdroje
1. Al-Zahrani, M. S., Bamshmous, S. O., Alhassani, A. A., Al-Sherbini, M. M.: Short-term effect of photodynamic therapy on periodontal status and glycemic kontrol of patiens with diabetes. J. Periodontol., roč. 80, 2009, č. 10, s. 1568–1573.
2. AISLP Kompendium:0016968 Ethyol inj. plv. sol.
3. Beiswanger, B. B., Mallatt, M. E., Mau, M. S., Jackson, R. D., Hennon, D. K.: The clinical effects of a mouthrinse containing 0.1% octenidine. J. Dent. Res., roč. 69, 1990, č. 2, s. 454–457.
4. Bhalla, M., Thami, G. P.: Acute urticaria due to dental eugenol. Allergy, roč. 58, 2003, č. 2, s. 158.
5. Bohuslavizki, K. H., Brenner, W., Klutmann, S., Hübner, R.-H., Lassmann, S., Feyerabend, B., Luttges, J., Tinnemeyer, S., Clausen, M., Henze, E.: Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J. Nucl. Med., roč. 39, 1998, s. 1237–1242.
6. Braham, P., Herron, C., Street, C., Darveau, R.: Antimicrobial photofynamic therapy may promote periodontal healing through multiple mechanisms. J. Periodontol., roč. 80, 2009, č. 11, s. 1790–1798.
7. Cervitec Liquid Antibacterial mouth rinsing solution. Ivoclar Vivadent Technical Data Sheet. Dostupné z: www.ivoclarvivadent.com.
8. Erazaban™ 10% Krém Docosanolum. Příbalový leták.
9. Flek, V.: Qutenza v klinických studiích. Bolest, roč. 13, 2010, č. 4, s. 197–199.
10. Fricová, J.: Postherpetická neuralgie – kasuistika. Bolest, roč. 12, 2007, č. 3, s. 144–145.
11. Ghannoum, M. A., Abu Elteen, K., Stretton, R. J., Whittaker, P. A.: Effects of octenidine and pirtenidine on adhesion of Candida species to human buccal epithelial cells in vitro. Arch. Oral Biol., roč. 35, 1990, č. 4, s. 249–253.
12. Guénette, S. A., Ross, A., Marieer, J. F., Beaudry, F., Vachon, P.: Pharmacokinetics of eugenol and its effects on thermal hypersensitivity in rats. Eur. J. Pharmacol., roč. 562, 2007, č. 1–2, s. 60–67.
13. Katz, D. H., Marcelletti, J F., Khalil, M. H., Pope, L. E., Katz, L. R.: Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. Proc. Natl. Acad. Sci. U. S. A., roč. 88, 1991, č. 2, s. 10825–10829.
14. Koukourakis, M. I.: Amifostine in clinical oncology: current use and future applications. Anti-cancer Drugs, roč. 13, 2002, č. 3, s. 181–209.
15. Kotas, R.: Primární nebo sekundární bolest hlavy? Bolest, roč. 12, 2009, č. 2, s. 73–77.
16. Leung, D. T., Sacks, S. L.: Docosanol: a topical antiviral for herpes labialis. Exper. Opin. Pharmacother., roč. 5, 2004, č. 12, s. 2567–2571.
17. Ma, C., Xie, J., Chen, Q., Wang, G., Zuo, S.: Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer. Cochrane Database of Systematic Reviews 2009, č. 4. Art. No.: CD007956. DOI: 10.1002/ /14651858.CD007956.pub2
18. Metodické pokyny pro farmakoterapii bolesti. Přepracované vydání. Bolest, roč. 12, 2009, Suppl 2.
19. Paleček, J.: Úloha TRPV1 v modulaci bolesti v experimentálních a klinických studiích. Bolest, roč. 13, 2010, Suppl. 1, s. 32–33.
20. Pope, L. E., Marcelletti, J. F., Katz, L. R., Lin, J. Y., Katz, D. H., Parish, M. L., Sper, P. G.: The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Res., roč. 40, 1998, č. 1–2, s. 85–94.
21. Porter, S. R., Scully, C., Hegarty, A. M.: An update of the etiology and management of xerostomia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., roč. 97, 2004, č. 1, s. 28–46.
22. Rohrer, N., Widmer, A. F., Waltimo, T., Kulik, E. M., Weiger, R., Filipuzzi-Jenny, E., Walter, C.: Antimicrobial efficacy of 3 oral antiseptics containing octenidine, polyhexamethylene biguanide, or Citroxx: can chlorhexidine be replaced? Infect. Control Hosp. Epidemiol., vol. 31, 2010, č. 7, s. 733–739.
23. Ryskova, L., Buchta, V., Slezak, R.: Photodynamic antimicrobial therapy. Centr. Eur. J. Biol., roč. 5, 2010, č. 4, s. 400–406.
24. Sarrami, N., Pemberton, M. N., Thornhill, M. H., Theaker, E. D.: Adverse reactions associated with the use of eugenol in dentistry. Br. Dent. J., roč. 193, 2002, č. 2, s. 253–255.
25. Sedlock, D. M., Bailey, D. M.: Microbicidal activity of octenidine hydrochloride, a new alkanediylbis[pyridine] germicidal agent. Antimicrob. Agents Chemother., roč. 28, 1985, č. 6, s. 786–790.
26. Sennhenn-Kirchner, S., Wolff, N., Klaue, S., Mergeryan, H., Borg-von Zepelin, M.: Decontamination efficacy of antiseptic agents on in vivo grown biofilms on rough titanium surfaces. Quintessence Int., roč. 40, 2009, č. 10, s. e80–e88.
27. Schupp, C. J., Holland-Cunz, S.: Persistent subcutaneous oedema and aseptic fatty tissue necrosis after using octenisept. Eur. J. Pediatr. Surg., roč. 19, 2009, č. 3, s. 179–183.
28. Slezák, R.: Preklinická parodontologie. 1. vyd. Hradec Králové, NUCLEUS HK, 2007, s. 69–76.
29. Slezák, R., Bittner, J., Ettlerová, K.: Malé ilustrované repetitorium. Alergická reakce s projevy v dutině ústní. LKS, roč. 14, 2004, č. 3, s. 19–20.
30. Slezák, R., Šustová, Z., Nováková, V.: Pokroky ve farmakoterapii chorob ústní sliznice. Čes. Stomat., roč. 109, 2009, č. 1, s. 7-14.
31. Takasaki, A. A., Aoki, A., Mizutani, K., Schwarz, F., Sculean, A., Wang, C.-Y., Koshi, G., Romanos, G., Ishikawa, I., Ozimi, Y.: Application of antimicrobial photodynamic therapy in periodontal and peri-implant diseases. Periodontology 2000, roč. 51, 2009: s. 109–140.
32. Tandjung, L., Waltimo, T., Hauser, I., Heide, P., Decker, E. M., Weiger, R.: Octenidine in root canal and dentine disinfection ex vivo. Int. Endod. J., roč. 40, 2007, č. 11, s. 845–851.
33. Tirali, R. E., Turan, Y., Akal, N., Karahan, Z. C.: In vitro antimicrobial activity of several concentrations of NaOCl and Octenisept in elimination of endodontic pathogens. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., roč. 108, 2009, č. 5, s. e117–e120.
34. van Winkelhoff, A. J., Winkel, E. G.: Antibiotics in periodontics: Right or wrong? J. Periodontol., roč. 80, 2009, č. 10: s. 1555–1558.
35. Vondráčková, D.: Farmakoterapie neuropatické bolesti. Klin. Farmakol. Farm., roč. 23, 2009, č. 4, s. 181–186.
36. Wainwright, M.: Antimicrobial application – photodynamic antimicrobial chemotherapy. In: Wainwright, M.: Photosensitizers in biomedicine. 1. vyd., Wiley-Blackwell, A John Wiley & Sons, Ltd., 2009, s. 237–258.
Štítky
Maxillofacial surgery Orthodontics Dental medicineČlánok vyšiel v časopise
Czech Dental Journal
2012 Číslo 1
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Advantages and Disadvantages of Dental Miniimplants – Ten Different Viewpoints
- Cleft Lip and Palate, the Initial Phase of Treatment Planning and Interdisciplinary Therapy for Patients in the Neonatal Age
- Advances in the Pharmacotherapy of Periodontal and Oral Mucosal Diseases
- The Use of Imaging Methods in the Diagnosis of Bisphosphonate-related Osteonecrosis of the Jaw